Sign In
Buy RVMD
$155.99
+4.68 (+3.09%)
At Close: Jun 03, 2026
Revolution Medicines Reports Second Quarter 2024 Financial Results and Update on Corporate Progress
04:05pm, Wednesday, 07'th Aug 2024
REDWOOD CITY, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancer
Revolution Medicines to Report Financial Results for Second Quarter 2024 After Market Close on August 7, 2024
04:05pm, Wednesday, 31'st Jul 2024
REDWOOD CITY, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancer
Top 3 Health Care Stocks That Should Keep You Up At Night This Quarter
08:16am, Tuesday, 16'th Jul 2024
As of July 16, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Original research published in Cancer Discovery reveals a RAS(ON) multi-selective inhibitor exhibited robust anti-tumor activity alone or in combination with a RAS(ON) G12C-selective inhibitor in prec
Revolution Medicines (RVMD) Moves 11.0% Higher: Will This Strength Last?
07:01am, Wednesday, 10'th Jul 2024
Revolution Medicines (RVMD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price
Revolution Medicines to Provide Update on RMC-6236 Pancreatic Ductal Adenocarcinoma Clinical Program on July 15, 2024
04:05pm, Monday, 08'th Jul 2024
REDWOOD CITY, Calif., July 08, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancer
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Revolution Medicines, Inc. (NASDAQ: RVMD)
09:00am, Monday, 08'th Jul 2024
NEW YORK , July 8, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Revolution Medicines, Inc. (NASDAQ: RVMD) on behalf of the company's shareholders. The investigation
The 7 Most Undervalued Under-$50 Stocks to Buy in June 2024
09:00am, Saturday, 08'th Jun 2024
For many investors, especially those who are just building a portfolio, undervalued stocks under $50 hold significant appeal. Investors can start a significant position, in terms of shares owned, for
Revolution Medicines to Participate in Goldman Sachs 45th Annual Global Healthcare Conference
04:05pm, Wednesday, 05'th Jun 2024
REDWOOD CITY, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancer
Revolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate Progress
04:02pm, Wednesday, 08'th May 2024
REDWOOD CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers
Revolution Medicines to Report Financial Results for First Quarter 2024 After Market Close on May 8, 2024
04:05pm, Wednesday, 01'st May 2024
REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers
Simultaneous publication and presentation of RMC-6236 chemical structure, preclinical data and case studies during the “KRAS: Broadening the Attack Beyond G12C with Small Molecules and Immuno-Oncolo
Two original papers in Nature highlight the discovery and translational implications of RMC-7977, a RAS(ON) multi-selective tri-complex inhibitor that exhibits unprecedented anti-tumor activity in pre
Revolution Medicines to Participate in Upcoming Investor Conferences
04:05pm, Thursday, 04'th Apr 2024
REDWOOD CITY, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cance
Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024
04:05pm, Thursday, 28'th Mar 2024
REDWOOD CITY, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cance
